OfficialPCAC vote — July 23–24, 2026

FDA Panel Backs 6 of 7 Peptides for Compounding — Vote Is Not Binding

The Pharmacy Compounding Advisory Committee met on July 23–24, 2026 and voted to recommend six of the seven peptides it reviewed for the Section 503A bulk drug substances list — the list that governs what compounding pharmacies may legally prepare. BPC-157 and KPV each cleared 8–6, with TB-500 and MOTS-c also backed. On the second day Epitalon was recommended and Semax 8–5, while Emideltide (DSIP) was rejected 6–7. The panel voted against the recommendation of the FDA’s own scientists, who had argued the human safety data was insufficient.

What's official: the advisory committee has voted and its recommendations are on the record. Six peptides were backed for the 503A list, one was rejected.

Nothing has changed legally. The vote is a non-binding recommendation. Until the FDA completes rulemaking, these peptides remain off the 503A list, compounding them is still not permitted, and selling them for human use still violates the FDCA.

🇺🇸

Peptide Laws in United States

US · Americas · 24 peptides tracked

Grey AreaEnforcement: Moderate

Are Peptides Legal in United States?

The United States regulates peptides under FDA oversight. The major development: on 30 October 2026 HHS published an "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances" (Federal Register doc 2026-22192, docket HHS-OASH-2026-0496). HHS will not take enforcement action against a state-licensed pharmacy, federal facility or licensed physician who compounds BPC-157, TB-500, Epitalon, KPV, MOTS-c or Semax under Section 503A, provided ten conditions are met. This is enforcement discretion, not approval: none of the six is FDA-approved, none has been added to the Section 503A bulk drug substances list, and the policy does not extend to Section 503B outsourcing facilities. A patient-specific prescription is still required. Critically, a compounded product may contain only ONE active ingredient, so multi-peptide stacks such as BPC-157 with TB-500 are outside the policy despite widespread reporting to the contrary. The bulk substance must come from an FDA-registered, CGMP-compliant facility with a certificate of analysis, serious adverse events must go to FDA MedWatch, and labelling must read "This is a compounded drug product. Not for resale." The policy runs until the FDA completes notice-and-comment rulemaking on the bulks list, and HHS may revisit it if a safety or quality signal emerges; public comments close around 13 November 2026. The six were recommended by the Pharmacy Compounding Advisory Committee at its 23-24 July 2026 meeting, against the advice of FDA's own review scientists. Emideltide (DSIP) was reviewed at the same meeting and rejected, so it remains barred from compounding. Buying any of these as a "research chemical" for human use remains unlawful. No peptide has been DEA-scheduled as a controlled substance. The FDA continues to enforce aggressively against compounded GLP-1 drugs (semaglutide, tirzepatide), with 85+ warning letters issued. Research-use-only labelling requirements have been fully enforceable since January 2026.

3

Legal

9

Grey Area

12

Prescription

Can You Buy Peptides in United States?

3 peptide(s) are legal to buy in United States, including NAD+, Glutathione, Vitamin B12. 12 peptide(s) require a valid prescription, including Tirzepatide, MOTS-c, TB-500, Semaglutide, Semax, and 7 more. 9 peptide(s) fall into a legal grey area: Retatrutide, Selank, AOD-9604, GHK-Cu, Ipamorelin, and 4 more. These may be available for research purposes but their legality for personal use is ambiguous.

Traveling to United States with Peptides

When traveling to United States with peptides, the legality depends on each peptide's classification. Prescription peptides (Tirzepatide, MOTS-c, TB-500, Semaglutide, Semax, and 7 more) typically require documentation such as a prescription or doctor's letter when crossing borders. Enforcement in United States is rated as "Moderate." Always declare pharmaceutical products at customs and carry documentation of any prescriptions.

New to peptides? Start with the basics on peptide.camp →

Need to source peptides for United States? Get verified wholesale quotes on peptide.broker →

Traveling to United States with peptides? TSA tips, packing guides & the peptide travel case on peptide.travel →

Peptide Regulations in United States

PeptideStatusRx RequiredSource
TirzepatidePrescriptionYesOfficial
MOTS-cPrescriptionYesOfficial
RetatrutideGrey AreaNoOfficial
SelankGrey AreaNoSecondary
AOD-9604Grey AreaNoSecondary
TB-500PrescriptionYesOfficial
GHK-CuGrey AreaNoSecondary
IpamorelinGrey AreaNoUnofficial
SemaglutidePrescriptionYesOfficial
CJC-1295Grey AreaNoUnofficial
SemaxPrescriptionYesOfficial
BPC-157PrescriptionYesOfficial
NAD+LegalNoSecondary
DSIPGrey AreaNoOfficial
EpithalonPrescriptionYesOfficial
GlutathioneLegalNoOfficial
HGHPrescriptionYesOfficial
KPVPrescriptionYesOfficial
LiraglutidePrescriptionYesOfficial
Melanotan IIGrey AreaNoOfficial
PT-141PrescriptionYesOfficial
MK-677Grey AreaNoOfficial
Vitamin B12LegalNoOfficial
EpitalonPrescriptionYesOfficial

About the sources on this page

Entries marked Official cite a government regulator, legislation or an official gazette. Entries marked Secondary rest on consultancy, law firm, news or academic reporting rather than the regulator itself. Entries marked Unofficial rest on sources that are not authoritative — which may include commercial sellers, medicine-import services or independent websites.

We show these entries rather than hiding them, but they should not be relied on. Nothing on this site is legal advice. Verify against the national regulator before acting, and if you can point us at a better source please submit an update.

Data is researcher-verified but not legal advice. Always consult local regulations before purchasing, importing, or traveling with peptides. Last verified: 2026-02-28.